Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Adalta Ltd

1AD.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.00

▲ +0.00%

Market Cap $6.80M · Vol 2.23M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.80M

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

40.00

Momentum

Beta

0.66

vs Market

52W High

$0.01

60.35% below

52W Low

$0.00

63.63% above

Volume

2.23M

Avg 1.71M

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

71.99%

Public shares

Shariah Compliance8 STANDARDS

✗ Adalta Ltd (1AD.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does 1AD.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-25.00%

-40.00%

-25.00%

YTD

+0.00%

+20.00%

-82.96%

-95.81%

Financials & Valuation

TTM · Annual

Total Revenue	$457.74K
Net Income	$-2,962,487.00
Revenue Growth (YoY)	-18.38%
Gross Margin	100.00%
Operating Margin	-638.73%
Net Profit Margin	-647.20%
ROE	N/A
ROA · ROIC	-116.72% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	2.24
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	3.21B

Technical Indicators

50-Day SMA	$0.00
200-Day SMA	$0.00
RSI (14)	40.00
Beta	0.66
52-Week High	$0.01
52-Week Low	$0.00

Volume Today	2.23M
Avg Daily Volume (30D)	1.71M
Relative Volume	1.30x
Volatility (10D)	249.35
Volatility (30D)	182.58
Free Float	71.99%

Analyst Consensus

N/A

Current Price $0.00

Mean Target N/A

52W Low$0.00 52W High$0.01

Current

Target

$0.00 $0.01

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG00D9SX1N6

ISINAU0000001AD2

CountryAustralia

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

AdAlta Limited is an Australia-based clinical-stage biotechnology company. The Company uses its i-body platform to discover and develop protein therapeutics addressing drug targets that are challenging for other technologies. The Company's first-in-class lead asset, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal. AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target, CXCR4. It is also engaged in developing i-body enabled Chimeric antigen receptor T cell (CAR-T) cells. It co-develops i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs.